Overview

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1

Status:
NOT_YET_RECRUITING
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 1/2a randomised, placebo controlled, double-blind study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALE1 on healthy adult subjects and adult patients with Hypophosphatasia (HPP).
Phase:
PHASE1
Details
Lead Sponsor:
Alesta Therapeutics